Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01624636 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01624636 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT01624636, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular age-related macular degeneration (AMD)
Interventions
- DRUG Placebo
- DRUG LFG316
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01624636
The ClinicalTrials.gov registry entry for NCT01624636 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01624636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01624636 about?
NCT01624636 is a clinical study titled "Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).". This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular age-related macular degeneration (AMD)
What is the current status of trial NCT01624636?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2012-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01624636?
The interventions under investigation include: Placebo (DRUG), LFG316 (DRUG).
Who is sponsoring clinical trial NCT01624636?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.